CYP2D6 Genotype and Adjuvant Tamoxifen

descriptionPublicationkeyboard_double_arrow_right Article 01 Aug 2014Publisher:WileyJournal:Clinical Pharmacology & Therapeutics, volume 96, pages 138-140 (issn: 0009-9236, eissn: 1532-6535,

Copyright policy )

Authors: D A, Berry;

doi: 10.1038/clpt.2014.96

pmid: 25056391

CYP2D6 Genotype and Adjuvant Tamoxifen

- Summary
- Subjects
- Metrics

Abstract

A study by Province et al. for the International Tamoxifen Pharmacogenomics Consortium (ITPC) appeared in a recent issue of this journal.1 In addition to discussing this study and biomarker studies in general, I provide an overall assessment of the evidence regarding testing for CYP2D6 in making clinical decisions regarding the use of tamoxifen in adjuvant breast cancer. Clinical Pharmacology & Therapeutics (2014); 96 2, 138–140. doi:10.1038/clpt.2014.96

Related Organizations

The University of Texas MD Anderson Cancer Center
United States

Keywords

Tamoxifen, Antineoplastic Agents, Hormonal, Cytochrome P-450 CYP2D6, Humans, Breast Neoplasms, Female

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	14
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%